Navigation Links
Spain's Hospital Ruber Internacional celebrates 20 years of excellence in Gamma Knife radiosurgery

MADRID, Nov. 20, 2013 /PRNewswire/ -- In 1993, Hospital Ruber Internacional became the world's 43rd Leksell Gamma Knife® center, treating its first patient – a 60-year-old female patient with a frontal meningioma – on August 23 of that year. Both the patient and the hospital's Radiosurgery and Functional Neurosurgery Unit are still going strong today. Operating Spain's only Gamma Knife system, the hospital has delivered radiosurgery to over 6,000 patients with a wide range of tumors and functional and vascular brain disorders.

Hospital Ruber Internacional will host the European Society of Leksell Gamma Knife at its annual congress, November 22-24.

Gamma Knife radiosurgery is a gentler alternative to traditional brain surgery for illnesses such as metastatic disease, which is cancer that has traveled to the brain from elsewhere in the body. With pinpoint accuracy, the system delivers up to thousands of low-intensity radiation beams to one or more targets in a single session. The latest Gamma Knife technology, Leksell Gamma Knife® Perfexion™ provides even greater speed and ease of use than previous models.

On the first day of the congress, Hospital Ruber Internacional will convene a symposium for members of the Society and referring physicians in Spain on the hospital's two decades of Gamma Knife experience.

As a pioneer of Gamma Knife radiosurgery, Hospital Ruber Internacional has operated successive versions of the system.

"We started with Gamma Knife B and switched to Gamma Knife C in 2000, then upgraded that system with the APS™ [Automatic Positioning System] in 2001," says Roberto Martinez, MD, Ruber neurosurgeon and Director of the Radiosurgery and Functional Neurosurgery Unit. "We acquired the Perfexion system in 2007, becoming the sixth Perfexion installed in Europe."

Perfexion is an ideal system to treat metastases – particularly for patients with multiple lesions, as the system's advanced collimator facilitates rapid isocenter changes. At Hospital Ruber Internacional, 80 percent of mets patients have more than one lesion, Dr. Martinez notes.

"The mean number of mets nowadays is four mets per patient," he says. "Referred patients will come to us with a diagnosis of one to two mets. However, we will perform an MRI with a double dose of contrast for mets patients, and we have found that in 70 percent of these cases, the number of mets is actually larger."

Patients with metastases represent about 20 percent of Ruber's Gamma Knife radiosurgery volume. Meningiomas and other benign tumors make up 40 percent, while 25 percent of radiosurgery cases are for vascular malformations. Although functional disorders, such as trigeminal neuralgia amount to just eight percent of Ruber's Gamma Knife cases now, they are a growing indication.

"Since 1998, we have treated 500 functional cases, mostly trigeminal neuralgia, but the trend is for more of these cases. We hope that in the near future that up to 12 percent of our indications are for functional disorders," Dr. Martinez says.

Installed in 48 countries, more than 300 Gamma Knife systems are currently in clinical use, with more than 700,000 patients treated worldwide.

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email:  
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: 
Time zone: ET: Eastern Time

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website:

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Chesapeake Urologys Dr. Brad Lerner, Chief of Urology at Union Memorial Hospital, Honored with Governors Citation for Outstanding Service
2. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
3. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
4. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
5. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
6. Physician-Patient Alliance for Health & Safety: Monitoring Technology for PCA Pumps Can Prevent Adverse Events: So Why Are Hospitals Not Using It?
7. Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
8. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
9. Hospitals Gain Time and Money Maximizing Distributor Value
10. Greenville Hospital System Achieves Dramatic Improvement in Hand Hygiene Compliance Rates Using New Technology from DebMed®
11. Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System
Post Your Comments:
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
Breaking Medicine News(10 mins):